{
    "clinical_study": {
        "@rank": "102718", 
        "acronym": "TERRANOVA", 
        "arm_group": [
            {
                "arm_group_label": "Benralizumab Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Benralizumab administered subcutaneously"
            }, 
            {
                "arm_group_label": "Benralizumab Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Benralizumab administered subcutaneously"
            }, 
            {
                "arm_group_label": "Benralizumab Arm C", 
                "arm_group_type": "Experimental", 
                "description": "Benralizumab administered subcutaneously"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered subcutaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in\n      symptomatic patients with moderate to very severe COPD who are receiving standard of care\n      therapies."
        }, 
        "brief_title": "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate to Very Severe Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:.\n\n          -  Informed consent.\n\n          -  Subjects 40-85 y.o.\n\n          -  Moderate to very severe COPD with Post Bronchodilator (BD) FEV1>20% and \u226465%.\n\n             -\u22652 moderate or \u22651 severe COPD exacerbation(s) required treatment or hospitalization\n             within 2-52 weeks prior to Visit1.\n\n          -  Modified Medical Research Council (mMRC) score \u22651 at Visit 1.\n\n          -  Treatment with double or triple therapy in the year prior to Visit 1, constant 2\n             weeks prior to Visit 1.\n\n          -  Tobacco history of \u226510 pack-years.\n\n          -  Women of childbearing potential must use a highly effective form of birth control\n             from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test\n             result at Visit 1.\n\n          -  Male subjects who are sexually active must be surgically sterile one year prior to\n             Visit 1 or use an adequate method of contraception from the first Investigational\n             Product (IP) dose until 16 weeks after their last dose.\n\n          -  Compliance with maintenance therapy during run-in \u226570%.\n\n        Exclusion criteria:\n\n          -  Clinically important pulmonary disease other than COPD or another diagnosed pulmonary\n             or systemic disease associated with elevated peripheral eosinophil counts.\n\n          -  Any disorder or major physical impairment that is not stable by Investigator opinion\n             and could affect: - subject safety\u2212study findings or their interpretation or\n             subject's ability to complete the entire study duration.\n\n          -  Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant\n             cardiovascular disorder that in Investigator's judgment may put the patient at risk\n             or negatively affect the study outcome.\n\n          -  Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization\n             for a COPD exacerbation within 2 weeks prior to Visit1.\n\n          -  Acute upper or lower respiratory infection requiring antibiotics or antiviral\n             medication within 2 weeks prior to Visit1.\n\n          -  Pneumonia within 8 weeks prior to Visit1.\n\n          -  Pregnant, breastfeeding, or lactating women.\n\n          -  Risk factors for pneumonia\n\n          -  History of anaphylaxis to any other biologic therapy.\n\n          -  Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right\n             ventricular failure.\n\n          -  Use of immunosuppressive medication within 28 days prior to randomisation.\n\n          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives\n             prior to Visit 1.\n\n          -  Evidence of active tuberculosis (TB), either treated or untreated, or latent TB\n             without an appropriate course of treatment.\n\n          -  Lung volume reduction surgery within the 6 months prior to Visit 1. History of\n             partial or total lung resection (single lobe or segmentectomy is acceptable).\n\n          -  Asthma as a primary or main diagnosis according to the Global Initiative for Asthma\n             (GINA) guidelines or other accepted guidelines.\n\n          -  Previous treatment with benralizumab.\n\n          -  Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "4850", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155660", 
            "org_study_id": "D3251C00004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Benralizumab Arm A", 
                "description": "Benralizumab subcutaneously on study week 0 until study week 48 inclusive", 
                "intervention_name": "Benralizumab Arm A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Benralizumab Arm B", 
                "description": "Benralizumab subcutaneously on study week 0 until study week 48 inclusive", 
                "intervention_name": "Benralizumab Arm B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Benralizumab Arm C", 
                "description": "Benralizumab subcutaneously on study week 0 until study week 48 inclusive", 
                "intervention_name": "Benralizumab Arm C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Benralizumab subcutaneously on study week 0 until study week 48 inclusive", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Obstructive Lung Diseases", 
            "Chronic Obstructive Pulmonary Disease", 
            "Lung Disease", 
            "Bronchial Diseases", 
            "COPD Exacerbation", 
            "Respiratory Tract Diseases"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montgomery", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodstock", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Towson", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buckley", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clabash", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shelby", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Killeen", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Longview", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels (Laeken)", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bras\u00edlia", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fortaleza", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Juiz de Fora", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santo Andr\u00e9", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sorocaba", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vit\u00f3ria", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dupnitsa", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kozloduy", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pazardzhik", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pernik", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petrich", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ruse", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vratsa", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yambol", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durango", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cusco", 
                        "country": "Peru"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Brazil", 
                "Bulgaria", 
                "Mexico", 
                "Peru"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations", 
        "other_outcome": [
            {
                "description": "European Quality of Life-5 Dimensions (EQ-5D-5L) questionnaire", 
                "measure": "Evaluation of the effect of benralizumab on general health status", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Blood eosinophils levels", 
                "measure": "Evaluation of the impact of benralizumab on blood eosinophil levels", 
                "safety_issue": "No", 
                "time_frame": "up to 60 weeks"
            }
        ], 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "ClinicalTrialTransparency"
        }, 
        "overall_contact_backup": {
            "email": "information.center@astrazeneca.com", 
            "last_name": "AstraZeneca Clinica Study Information", 
            "phone": "+ 800-236-9933"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital, Pulmonary Division, 75 Francis Street, PBB Clinics 3, Boston, MA 02115", 
            "last_name": "Bartolome R. Celli, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Peru: Ministry of Health", 
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Ukraine: Ministry of Health", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Denmark: Danish Medicines Agency (DKMA) Leademiddelstyrelsen Axel heides", 
                "Norway: Norwegian Medicines Agency (NoMA)", 
                "Sweden: Medical Products Agency", 
                "Turkey: Ministry of Health", 
                "Brazil: National Health Surveillance Agency", 
                "Mexico: Federal Commission for Sanitary Risks Protection", 
                "Israel: Ethics Commission", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Annual COPD (Chronic Obstructive Pulmonary Disease) exacerbation rate.", 
            "measure": "Evaluation of the effect of benralizumab on COPD exacerbations in subjects with moderate to very severe COPD", 
            "safety_issue": "No", 
            "time_frame": "Immediately following administration of study drug up to 56 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155660"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "St. George's Respiratory Questionnaire (SGRQ ), Chronic Obstructive Pulmonary Disease assessment tool (CAT)", 
                "measure": "Evaluation of the effect of benralizumab on health status/health-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Pre-dose/pre-bronchodilator Forced expiratory volume in one second (FEV1) at the study center", 
                "measure": "Evaluation of the effect of benralizumab on pulmonary function", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Baseline/Transitional Dyspnea Index (BDI/TDI)", 
                "measure": "Evaluation of the effect of benralizumab on respiratory symptoms", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Total rescue medication use (average puffs/day), recorded by patient using electronic diary", 
                "measure": "Evaluation of the effect of benralizumab on rescue medication use", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Number of nights with awakening due to COPD, recorded by patient using electronic diary", 
                "measure": "Evaluation of the effect of benralizumab on nocturnal awakenings", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) - Patient-reported Outcome questionnaire", 
                "measure": "Evaluation of the effect of benralizumab on the severity, frequency and duration of Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) - Patient-reported Outcome questionnaire defined events", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Annual rate of hospitalizations, combined hospitalizations and emergency department visits, unscheduled visits and healthcare encounters due to COPD", 
                "measure": "Evaluation of the effect of benralizumab on healthcare resource utilization", 
                "safety_issue": "No", 
                "time_frame": "up to 56 weeks"
            }, 
            {
                "description": "Pharmacokinetics (PK) - steady-state serum pre-dose concentration", 
                "measure": "Evaluation of the benralizumab concentration in serum", 
                "safety_issue": "No", 
                "time_frame": "up to 60 weeks"
            }, 
            {
                "description": "Adverse Events/ Serious Adverse Events (AE/SAE) - Laboratory variables - 12 lead Electrocardiogram (ECG) - Physical Examination - Vital Signs", 
                "measure": "Assessment of the safety and tolerability of benralizumab", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline visit up to 56 weeks"
            }, 
            {
                "description": "Determination of Anti-drug antibodies (ADA)", 
                "measure": "Evaluation of the immunogenicity of benralizumab", 
                "safety_issue": "No", 
                "time_frame": "up to 60 weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}